Value of PD-L1, PD-1, and CTLA-4 Expression in the Clinical Practice as Predictors of Response to Nivolumab and Ipilimumab in Monotherapy in Patients With Advanced Stage Melanoma

Conclusions: Nivolumab produces a better response compared with ipilimumab in patients with melanoma. The IHC expression of PD‐L1 and CTLA-4 are associated with a higher response rate to nivolumab and ipilimumab, respectively, and better PFS, but the existence of responder patients with negative expression suggests that they are not adequate biomarkers to select candidate patients for ICI in the clinical practice.
Source: The American Journal of Dermatopathology - Category: Pathology Tags: Original Study Source Type: research